Ionis Pharmaceuticals | IONS

Stock Price
61.23
Daily Change
1.88 3.17%
Monthly
50.48%
Yearly
30.58%
Q3 Forecast
60.72

Peers Price Chg Day Year Date
Celltrion 169,000.00 -1,200.00 -0.71% -11.61% Sep/05
Cspc Pharmaceutical 11.19 0.36 3.32% 140.13% Sep/05
Sino Biopharmaceutical 8.91 0.52 6.20% 183.76% Sep/05
Astellas Pharma 1,701.00 22.50 1.34% -5.55% Sep/05
Zhangzhou Pientzehuang Pharmaceutical 203.87 0.94 0.46% 0.69% Sep/05
Kangmei Pharma 2.03 0 0% 15.34% Sep/05
Agios Pharmaceuticals 36.01 -0.12 -0.33% -16.80% Sep/05
Adcock Ingram Holdings 7,187.00 -13.00 -0.18% 10.77% Sep/05
Alnylam Pharmaceuticals 452.00 -1.54 -0.34% 83.16% Sep/05
Arrowhead Research 29.08 1.08 3.86% 30.87% Sep/05
BioMarin Pharmaceutical 57.77 1.02 1.80% -31.29% Sep/05
Divis Laboratories Ltd 6,009.00 -124.50 -2.03% 16.96% Sep/05
Exelixis 37.88 0.50 1.34% 50.62% Sep/05
Knight Therapeutics 6.44 0 0% 14.18% Sep/05
Halozyme Therapeutics 74.93 1.53 2.08% 26.55% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Malin Corporation 8.00 0 0% 29.03% Sep/01
Moderna 25.14 0.86 3.54% -65.54% Sep/05
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neurocrine Biosciences 144.10 3.70 2.64% 19.91% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Novartis 103.98 0.06 0.06% 5.46% Sep/05
Organigram Holdings 2.28 0.08 3.64% -4.20% Sep/05
OPKO Health 461.10 2.60 0.57% -21.46% Sep/04
Pfizer 24.88 0.34 1.39% -12.95% Sep/05
Pharma Mar 88.40 -2.80 -3.07% 116.88% Sep/05
PTC Therapeutics 57.26 -0.75 -1.29% 81.55% Sep/05
Qiagen NV 40.39 0.18 0.44% -1.38% Sep/06
Ultragenyx Pharmaceutical 31.82 0.54 1.73% -42.40% Sep/05
Regeneron Pharmaceuticals 573.38 6.16 1.09% -49.30% Sep/05
Roche Holding 274.20 -1.50 -0.54% 2.62% Sep/06
Laboratorios Farma 59.65 -0.10 -0.17% -26.18% Sep/05
Sarepta Therapeutics 18.71 0.25 1.35% -85.49% Sep/05
Sartorius 193.20 4.90 2.60% -23.42% Sep/06
Tilray 1.64 0.06 3.80% -25.45% Sep/05
Vertex Pharmaceuticals 396.12 -0.81 -0.20% -15.39% Sep/05


Ionis Pharmaceuticals traded at $61.23 this Friday September 5th, increasing $1.88 or 3.17 percent since the previous trading session. Looking back, over the last four weeks, Ionis Pharmaceuticals gained 50.48 percent. Over the last 12 months, its price rose by 30.58 percent. Looking ahead, we forecast Ionis Pharmaceuticals to be priced at 60.72 by the end of this quarter and at 59.22 in one year, according to Trading Economics global macro models projections and analysts expectations.

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).